Table 2.
Amikacin pharmacokinetics in patients with or without renal dysfunction
| All (n = 74) |
CrCl <50 ml/min (n = 38) |
CrCl >50 ml/min (n = 36) |
|
|---|---|---|---|
| Vd1 (central) (L) | 0.23 (0.18-0.28) | 0.23 (0.19-0.35) | 0.22 (0.17-0.26) |
| Vd2 (peripheral) (L) | 0.18 (0.11-0.23) | 0.19 (0.12-0.29) | 0.18 (0.11-0.23) |
| Vss (L/kg) | 0.41 (0.29-0.51) | 0.42 (0.31-0.54) | 0.40 (0.28-0.49) |
| t1/2 (hours) | 4.6 (3.2-7.8) | 7.6 (4.6-13.2) | 3.3 (2.5-4.6)a |
| CL (ml/min/kg) | 1.98 (1.28-3.54) | 1.29 (0.84-2.01) | 3.49 (1.94-5.04)a |
| AUC (mg × h/ml) | 798 (478-1285) | 1,177 (833-1961) | 466 (368-763)a |
| Cmax (μg/ml) | 91.7 (73.1-112.8) | 91.0 (70.6-112.8) | 92.3 (74.1-109.4) |
| Peak (μg/ml) | 72.7 (61.7-90.2) | 71.5 (57.3-86.3) | 75.7 (63.1-92.9) |
| Cmin (μg/ml) | 6.7 (2.1-15.4) | 15.4 (8.0-21.4) | 2.6 (1.3-6.0)a |
Data are expressed as median (IQR). a p < 0.001. AUC, area under the curve; t1/2, elimination half-time; CL, clearance; CrCl, creatinine clearance; Vd, volume of distribution; Vss, total volume of distribution.